Skip to content
lifestyle.wordsjournal.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Palvella Therapeutics Inc.
Palvella Therapeutics Appoints James R. Treat, M.D., Nationally Recognized Pediatric Dermatologist as Chief Medical Officer
September 9, 2026
Palvella Therapeutics to Participate in Upcoming Healthcare Investor Conferences
September 2, 2026
Palvella Therapeutics Completes Rolling Submission of New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
August 31, 2026
Palvella Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference
August 5, 2026
Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 4, 2026
Palvella Therapeutics Chief Scientific Officer Jeff Martini, Ph.D. Selected to Present at Upcoming FDA Public Workshop on Drug Repurposing
July 30, 2026
Palvella Therapeutics to Host Second Quarter 2026 Financial Results and Corporate Update Conference Call on August 4, 2026
July 28, 2026
Palvella Therapeutics Announces New Data from the Phase 2 TOIVA Trial of QTORIN™ Rapamycin in Cutaneous Venous Malformations Presented at the 83rd Annual Meeting of the Society for Investigative Dermatology
May 15, 2026
Palvella Therapeutics Announces Uplisting to the Nasdaq Global Market
May 13, 2026
Palvella Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 7, 2026
1
2
3
Next Page
→